Trial Profile
Dolutegravir in Pregnant HIV Mothers and Their Neonates
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Nov 2023
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Efavirenz
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms DolPHIN-2
- 10 Nov 2023 Status changed from active, no longer recruiting to completed.
- 26 Oct 2022 Results from DolPHIN-2, ADVANCE, NAMSAL and VISEND, comparing rates of virological failure (VF)and re-suppression in four randomised trials of dolutegravir (DTG), efavirenz (EFV) and protease inhibitors , presented at the 16th International Congress on Drug Therapy and HIV Infection
- 26 Oct 2022 Data of adverse birth outcomes from 5 studies DolPHIN-1, DolPHIN-2, ADVANCE, NAMSAL and IMPAACT-2010 were presented at the 16th International Congress on Drug Therapy and HIV Infection.